Advertisement

Intervals between bone mineral density testing with dual-energy X-ray absorptiometry scans in clinical practice

  • H. Lyu
  • K. Yoshida
  • S.K. Tedeschi
  • S. Zhao
  • C. Xu
  • S.U. Nigwekar
  • B.Z. Leder
  • D.H. SolomonEmail author
Short Scientific Communication

Abstract

Summary

Intervals between dual-energy X-ray absorptiometry (DXA) scans were evaluated in a large cohort of typical clinical practice. Intensive DXA scanning (intervals < 23 months) decreased substantially, from 16.7% in 2006 to 6.7% in 2015.

Introduction

Serial dual-energy X-ray absorptiometry (DXA) measurements are suggested for patients at high risk of fractures. However, little is known about how often DXA testing occurs in clinical practice.

Methods

We examined time intervals between DXA testing for monitoring purpose at two academic medical centers in the US between 2004 and 2017. The primary outcome was the presence of testing intervals < 23 months (termed “intensive DXA testing”). A generalized linear mixed model was used to evaluate the association between selected patient-level clinical factors and intensive DXA testing.

Results

Forty-nine thousand four hundred ninety-four DXA tests from 20,200 patients were analyzed. The mean time interval between scans was 36 ± 21 months. Only 11.1% of the repeated DXA testing met the criterion for intensive testing. The percentage of intensive DXA testing dropped from 16.7% in 2006 to 6.7% in 2015 (p for trend < 0.001). After adjusting for age, gender, number of outpatient visits, and calendar year, correlates of intensive DXA testing included a baseline T-score < −2.5 at any anatomic site (OR, 4.8; 95%CI, 4.0–5.7), active use of drugs for osteoporosis (OR, 1.6; 95%CI, 1.3–1.9), and active use of glucocorticoids (OR, 1.3; 95%CI, 1.2–1.4).

Conclusions

The predictors of intensive DXA testing suggest that this practice is used preferentially in patients with multiple risk factors and to monitor the response to pharmacotherapy. However, intensive DXA testing has become less common in real-world clinical practice over the last decade. Further studies are required to better define the optimal use of bone mineral density testing in this vulnerable population.

Keywords

Dual-energy X-ray absorptiometry Osteoporosis Repeated scan Short interval 

Notes

Funding information

This work was supported by the NIH-P30-AR072577 (VERITY). HL received scholarship from Chinese PLA General Hospital. KY received financial support for his doctoral study from Harvard T.H. Chan School of Public Health (partially supported by training grants from Takeda, Pfizer, Bayer, and ASISA) and Honjo International Scholarship Foundation. SKT received support from the Lupus Foundation of America Career Development Award. DHS receives salary support from NIH-K24AR055989.

Compliance with ethical standards

Conflict of interest

None.

Supplementary material

198_2019_4847_MOESM1_ESM.pdf (188 kb)
ESM 1 (PDF 187 kb)

References

  1. 1.
    Cosman F, de Beur SJ, LeBoff MS et al (2014) Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int 25:2359–2381CrossRefGoogle Scholar
  2. 2.
    International Society for Clinical Densitometry (2015) Official positions of the International Society for Clinical Densitometry. https://iscd.app.box.com/v/OP-ISCD-2015-Adult. Accessed 12 Nov 2018
  3. 3.
    Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, Kleerekoper M, Lewiecki EM, Miller PD, Narula HS, Pessah-Pollack R, Tangpricha V, Wimalawansa SJ, Watts NB (2016) American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract 22:1–42CrossRefGoogle Scholar
  4. 4.
    Qaseem A, Forciea MA, McLean RM et al (2017) Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Intern Med 166:818–839CrossRefGoogle Scholar
  5. 5.
    Combs BP, Rappaport M, Caverly TJ, Matlock DD (2013) “Due” for a scan: examining the utility of monitoring densitometry. JAMA Intern Med 173:2007–2009CrossRefGoogle Scholar
  6. 6.
    Morden NE, Schpero WL, Zaha R, Sequist TD, Colla CH (2014) Overuse of short-interval bone densitometry: assessing rates of low-value care. Osteoporos Int 25:2307–2311CrossRefGoogle Scholar
  7. 7.
    Nakasian SS, Rassen JA, Franklin JM (2017) Effects of expanding the look-back period to all available data in the assessment of covariates: effects of expanding the look-back approach. Pharmacoepidemiol Drug Saf 26:890–899CrossRefGoogle Scholar
  8. 8.
    Solomon DH, Johnston SS, Boytsov NN, McMorrow D, Lane JM, Krohn KD (2014) Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res 29:1929–1937CrossRefGoogle Scholar
  9. 9.
    International Society for Clinical Densitometry Comment on the Centers for Medicare & Medicaid Services (CMS) Calendar Year (CY) 2017 Hospital outpatient prospective payment system (OPPS) and ambulatory surgical center (ASC) payment system policy changes, Quality Provisions, and Payment Rates Proposed Rule (CMS-1656-P)Google Scholar
  10. 10.
    Zhang J, Delzell E, Zhao H, Laster AJ, Saag KG, Kilgore ML, Morrisey MA, Wright NC, Yun H, Curtis JR (2012) Central DXA utilization shifts from office-based to hospital-based settings among medicare beneficiaries in the wake of reimbursement changes. J Bone Miner Res Off J Am Soc Bone Miner Res 27:858–864CrossRefGoogle Scholar
  11. 11.
    Yoo JW, Nakagawa S, Kim S (2012) Effect of reimbursement reductions on bone mineral density testing for female Medicare beneficiaries. J Women's Health 21:1144–1148CrossRefGoogle Scholar
  12. 12.
    Nelson HD, Morris CD, Kraemer DF, et al (2001) Osteoporosis in postmenopausal women: diagnosis and monitoring: summary. Agency for Healthcare Research and Quality (US)Google Scholar
  13. 13.
    White VanGompel EC, Franks P, Robbins JA, Fenton JJ (2017) Incidence and predictors of repeat bone mineral densitometry: a longitudinal cohort study. J Gen Intern Med 32:1090–1096CrossRefGoogle Scholar
  14. 14.
    Tannenbaum C, Clark J, Schwartzman K, Wallenstein S, Lapinski R, Meier D, Luckey M (2002) Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab 87:4431–4437CrossRefGoogle Scholar
  15. 15.
    Yu EW, Finkelstein JS (2012) Bone density screening intervals for osteoporosis: one size does not fit all. JAMA 307:2591–2592CrossRefGoogle Scholar
  16. 16.
    Tosteson ANA, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM, Pressman AR, Ettinger B (2003) Early discontinuation of treatment for osteoporosis. Am J Med 115:209–216CrossRefGoogle Scholar
  17. 17.
    Schott AM, Ganne C, Hans D, Monnier G, Gauchoux R, Krieg MA, Delmas PD, Meunier PJ, Colin C (2007) Which screening strategy using BMD measurements would be most cost effective for hip fracture prevention in elderly women? A decision analysis based on a Markov model. Osteoporos Int 18:143–151CrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2019

Authors and Affiliations

  • H. Lyu
    • 1
    • 2
  • K. Yoshida
    • 3
  • S.K. Tedeschi
    • 4
  • S. Zhao
    • 4
    • 5
  • C. Xu
    • 4
  • S.U. Nigwekar
    • 6
  • B.Z. Leder
    • 7
  • D.H. Solomon
    • 4
    • 8
    Email author
  1. 1.Department of MedicineHarvard Medical SchoolBostonUSA
  2. 2.Department of OrthopedicsChinese PLA General HospitalBeijingChina
  3. 3.Departments of Epidemiology and BiostatisticsHarvard T.H. Chan School of Public HealthBostonUSA
  4. 4.Division of Rheumatology, Immunology and AllergyBrigham and Women’s HospitalBostonUSA
  5. 5.Institute of Ageing and Chronic DiseaseUniversity of LiverpoolLiverpoolUK
  6. 6.Division of Nephrology, Department of MedicineMassachusetts General HospitalBostonUSA
  7. 7.Endocrine Unit, Department of MedicineMassachusetts General Hospital and Harvard Medical SchoolBostonUSA
  8. 8.Division of Pharmacoepidemiology and Pharmacoeconomics, Department of MedicineBrigham and Women’s Hospital and Harvard Medical SchoolBostonUSA

Personalised recommendations